Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 13, 2020Diabetes TherapyOpen Access

Systemic Delivery of siRNA Specific for Silencing TLR4 Gene Expression Reduces Diabetic Cardiomyopathy in a Mouse Model of Streptozotocin-Induced Type 1 Diabetes

View Full Paper
Ask AI
Bookmark
Share

Key result

Systemic delivery of TLR4 siRNA significantly preserved left ventricular ejection fraction (57.95% vs. 45.34%) and reduced hypertrophy, fibrosis, and inflammation in a mouse model of diabetic cardiomyopathy.

Why the study?

TLR signaling triggers diabetic cardiomyopathy through mechanisms including TLR4 upregulation, prompting this study to delineate the role of TLR4 in diabetic cardiomyopathy.

Does systemic delivery of TLR4 siRNA prevent or reduce diabetic cardiomyopathy in a mouse model of streptozotocin-induced type 1 diabetes?

Population

C57BL/6 mice with streptozotocin-induced diabetes

Comparison

TLR4 siRNA vs scrambled siRNA

Design

Animal experimental study

Authors

YZYuwei ZhangYLYang LiXHXuefang Huang

Discussion

Loading...

Member takes

Overview

May support TLR4 as target in diabetic cardiomyopathy models; hypothesis-generating and should not change practice.

Structured PICO

Does systemic delivery of TLR4 siRNA prevent or reduce diabetic cardiomyopathy in a mouse model of streptozotocin-induced type 1 diabetes?

P
Population
Male adult C57BL/6 mice, aged 6 to 8 weeks, with streptozotocin (STZ)-induced type 1 diabetes (n=30) and non-diabetic controls (n=10). Total n=40. Key inclusion: fasting blood glucose ≥16.7 mM at 72 h after STZ injections.
I
Intervention
5 μg of TLR4 small interfering RNA (siRNA) mixed with nanoparticle transfection reagent, administered intravenously via tail vein, repeated 4 weeks after the first treatment.
C
Comparator
5 μg of scrambled siRNA or untreated (sham).
O
Outcome
Myocardial function evaluated by echocardiography (fractional shortening and ejection fraction) and cardiac histopathology (hypertrophy, fibrosis, inflammation) at 8 weeks after treatment.surrogate

Main Result

Absolute Event Rate: 57.95% vs 45.34%

p-value: p=<0.05

Systemic silencing of the TLR4 gene using siRNA attenuates cardiac hypertrophy, fibrosis, inflammation, and myocardial dysfunction in a mouse model of type 1 diabetes.

Limitations

  • The major obstacle in clinical application of siRNA lies in developing safe and effective methods of delivering siRNA to target cells

Cite This Study

Zhang et al. (2020) studied Diabetic cardiomyopathy (n=40). TLR4 siRNA vs. Scrambled siRNA was evaluated on Ejection fraction (EF) (p=<0.05). Systemic delivery of TLR4 siRNA significantly preserved left ventricular ejection fraction (57.95% vs. 45.34%) and reduced hypertrophy, fibrosis, and inflammation in a mouse model of diabetic cardiomyopathy.

synapsesocial.com/papers/6a1ac0fc7ff99bba06461fd7https://doi.org/10.1007/s13300-020-00802-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inhibition of Toll-like Receptor-4 expression for amelioration of myocardial injury in diabetes: A meta-analysis2022 · 6 citations
  2. 2TLR4 regulates cardiac lipid accumulation and diabetic heart disease in the nonobese diabetic mouse model of type 1 diabetes2012 · 98 citations
  3. 3Hyperinsulinemia Down-Regulates TLR4 Expression in the Mammalian Heart2014 · 4 citations
  4. 4TAK-242 alleviates diabetic cardiomyopathy via inhibiting pyroptosis and TLR4/CaMKII/NLRP3 pathway2024 · 4 citations
  5. 5Loss of toll-like receptor 4 ameliorates cardiovascular dysfunction in aged mice2021 · 16 citations